MedTrace Logo

High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant

NCT01941680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-06-03

No results posted yet for this study

Summary

Patients are recruited at diagnosis or at relapse of ATLL-HR in French Caribbean islands and Guyana. They all receive Zidovudine and Pegylated Interferon (ZPI). For patients younger than 65 years old, an allogeneic donor is searching out. Patients included at relapse and with lymphoma clinico-biological subtype also receive chemotherapy (CT). Responses are assessed during ZPI+/-CT and eligible patients (depending on age, comorbidities and response criteria) receive allogeneic transplant. Patient follow-up is planned for 3 years old

Conditions

Sponsors & Collaborators

  • University Hospital Center of Martinique

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2018-02-28
Completion
2021-03-31

Countries

  • Guadeloupe
  • Martinique

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01941680 on ClinicalTrials.gov